UNITY Biotechnology
285 East Grand Avenue
South San Francisco
CA
94080
United States
Website: https://unitybiotechnology.com/
36 articles with UNITY Biotechnology
-
While showing early promise, Senolytics is a new field and most of the research is still in academic centers – most notably, the Mayo Clinic.
-
Unity announced advances in diabetic macular edema via Phase II study results, potentially allowing its recipients to return to tasks of daily living, like driving.
-
UNITY Biotechnology Announces Additional Data from Phase 1 Study of UBX1325 in Advanced Vascular Eye Disease
2/14/2022
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], today announced that 24-week clinical data from the Phase 1 study of UBX1325 was presented by Robert Bhisitkul, M.D., Ph.D., professor of ophthalmology and director of the Retina Fellowship at University of California, San Francisco, at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference on Saturday, February 12, 2022.
-
At the annual J.P. Morgan conference, the biotech industry launched its encore to a wildly successful 2020 – virtually. And, as is becoming the common scenario, attendees found both pros and cons to our new (temporary?) reality.
-
Ascentage Pharma's Licensee UNITY Biotechnology Announces Milestone Reached in Clinical Development of Treatments for Age-Related Disease, Leading to Milestone Payment
12/22/2020
Ascentage Pharma, a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases, announced that its licensee, UNITY Biotechnology, has dosed the first patient in a Phase I clinical study of drug candidate UBX1325 in patients with diabetic macular edema.
-
UNITY Biotechnology launched a restructuring program to focus on cellular senescence in ophthalmology and neurology. As part of the plan, it is decreasing its workforce by about 30% to optimize capital.
-
Clinical Catch-Up: August 17-21
8/24/2020
It was a relatively quiet week for clinical trial news. Here’s a look. -
UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
UNITY Biotechnology, Inc. Reports First Quarter 2020 Financial Results and Business Updates
5/7/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today reported financial results for the first quarter ended March 31, 2020.
-
UNITY Biotechnology, Inc. to Announce First Quarter 2020 Financial Results
5/4/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it will report financial results for the first quarter ended March 31, 2020, on Thursday, May 7, 2020 after NASDAQ market close.
-
UNITY Biotechnology Completes Enrollment in Phase 1b Study of UBX0101
3/31/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced updates related to UBX0101.
-
UNITY Biotechnology Announces Start of New CEO and New Employment Inducement Grants
3/30/2020
UNITY Biotechnology, Inc. today announced that Anirvan Ghosh, Ph.D., has officially joined the company as Chief Executive Officer.
-
UNITY Biotechnology Appoints Anirvan Ghosh, Ph.D. as Chief Executive Officer
3/2/2020
UNITY Biotechnology today announced the appointment of Anirvan Ghosh, Ph.D., as CEO and member of the Board of Directors, effective March 30, 2020.
-
UNITY Biotechnology Provides Pipeline and Business Updates
2/25/2020
UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today provided pipeline and business updates.
-
UNITY Biotechnology, Inc. to Participate in the Cowen and Company 40th Annual Health Care Conference
2/24/2020
UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that Keith Leonard, chairman and chief executive officer, will present at the upcoming Cowen and Company 40th Annual Health Care Conference.
-
Ascentage Pharma Announces New License with Unity Biotechnology
1/8/2019
Ascentage is eligible to receive an upfront payment in shares of UNITY's common stock and cash milestone payments and royalties based on clinical development and commercial sales milestones of UBX1967.
-
The Baltimore Longitudinal Study of Aging was launched in 1958 by the National Institutes of Health. The idea was to follow and study the lives of healthy, active people over their lifetimes, rather than after they were dead.
-
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.